How Will the Market React to Inhibrx Inc (INBX) Stock Getting a Bullish Rating

Inhibrx Inc (INBX) stock has risen 23.54% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Inhibrx Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on INBX!

See Full INBX Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With INBX Stock Today?

Inhibrx Inc (INBX) stock is trading at $22.36 as of 3:05 PM on Friday, Sep 1, a rise of $0.96, or 4.49% from the previous closing price of $21.40. The stock has traded between $21.63 and $22.48 so far today. Volume today is 236,228 compared to average volume of 279,006. To screen for more stocks like Inhibrx Inc click here.

More About Inhibrx Inc

Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency. Click Here to get the full Stock Report for Inhibrx Inc stock.